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Abstract
Background: The non-pharmacological approach to cholesterol control in patients with hyperlipidemia is based
on the promotion of a healthy diet and physical activity. Thus, to help patients change their habits, it is essential to
identify the most effective approach. Many efforts have been devoted to explain changes in or adherence to
specific health behaviors. Such efforts have resulted in the development of theories that have been applied in
prevention campaigns, and that include brief advice and counseling services. Within this context, Motivational
Interviewing has proven to be effective in changing health behaviors in specific cases. However, more robust
evidence is needed on the effectiveness of Motivational Interviewing in treating chronic pathologies -such as
dyslipidemia- in patients assisted by general practitioners. This article describes a protocol to assess the
effectiveness of MI as compared with general practice (brief advice), with the aim of improving lipid level control
in patients with dyslipidemia assisted by a general practitioner.
Methods/Design: An open, two-arm parallel, multicentre, cluster, controlled, randomized, clinical trial will be
performed. A total of 48-50 general practitioners from 35 public primary care centers in Spain will be randomized
and will recruit 436 patients with dyslipidemia. They will perform an intervention based either on Motivational
Interviewing or on the usual brief advice. After an initial assessment, follow-ups will be performed at 2, 4, 8 and 12
months. Primary outcomes are lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) and
cardiovascular risk. The study will assess the degree of dietary and physical activity improvement, weight loss in
overweight patients, and adherence to treatment guidelines.
Discussion: Motivational interview skills constitute the primary strategies GPs use to treat their patients. Having
economical, simple, effective and applicable techniques is essential for primary care professionals to help their
patients change their lifestyle and improve their health. This study will provide scientific evidence on the
effectiveness of Motivational interviewing, and will be performed under strict control over the data collected,
ensuring the maintenance of therapeutic integrity.
Trials Registration: ClinicalTrials.gov (NCT01282190).
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There is enough scientific evidence on the causal rela-
tion between increased plasma cholesterol levels and the
incidence of cardiovascular events. Similarly, such risk is
reduced when cholesterol levels decrease [1]. Arterio-
sclerosis is an inflammatory process triggered by a num-
ber of cardiovascular risk factors (CRFs). The risk
attributable to any blood cholesterol level also depends
heavily on the coexistence of other CRFs [2]. Therefore,
the cardiovascular event risk in patients with dyslipide-
mia is directly related to the total cardiovascular risk,
rather than to their plasma lipid profile [3].
From the perspective of primary care (PC) the role of
general practitioners -GPs- is essential in the prevention
of dyslipidemia, both in terms of detection and of the
therapeutic approach employed. In this sense, we know
that healthy lifestyle recommendations are based on
more robust scientific evidence (grade A and B recom-
mendations) than the pharmacological treatment itself,
when prescribed (grade D recommendation) [4]. There
are previous successful interventions for smoking and
alcohol cessation and for the promotion of healthy
habits [5]. However, the impact of such interventions
was from low to moderate, and most of the measures
are recommended for their effectiveness in reducing
morbidity and mortality, rather than for the fact that
t h e r ei ss t r o n ge v i d e n c et h a tP Ci n t e r v e n t i o n sh e l p
change health behaviors [6].
Consequently, it is essential to identify the most effec-
tive strategy that GPs could use to help their patients
change habits associated to cardiovascular health. Many
efforts have been devoted to develop theories that
explain changes or adherence to specific health beha-
viors. The objective is to make such theories operative
on the fourth stage of Miller’s pyramid, with a reason-
able cost-benefit balance. To date, many of these the-
ories have resulted in prevention activities including
brief advice and counseling [7]. Within this context,
Motivational Interviewing -MI- has gained in popularity
during the recent years. It have proven to be effective in
helping patients with specific diseases and under specific
conditions change health behaviors [8]. MI was initially
used to help people approach their ambivalences and
change their behavior patterns [9]. MI was a trans-
theoretical model derived from the Client-Centered
Therapy, which combined an empathetic and under-
standing style of counseling [10]. Simultaneously, it is a
directive method for resolving ambivalence in the direc-
tion of change. MI has evolved into “a clinical style
aimed at eliciting patients own motivations for making
changes in behaviors in the interests of their health”
[11]. In its different applications, MI has proven to be
more effective than other models as the classic
informative, as effective as Behavioral Cognitive Therapy
with less cost in time, and it is even more effective than
some pharmacological therapies in specific cases
[12,13].”
As a result, the need has arisen for valid and reliable
instruments allowing us to assess to what extent GPs
use MI. In this sense, scant scientific literature is avail-
able, and only two instruments are worth of mention:
an instrument that is based on an orthodox theoretical
approach to MI: the Motivational Interviewing Skills
Code: MISC [14], and its synthesized version -more
applicable-, the Motivational Interviewing Treatment
Integrity or MITI [15].
The second instrument is known as the Behavior
Change Counseling Index, and it is based on Behavior
Change Counseling [16]. Both have been proved to be
effective and reliable for assessing MI skills. However, to
date, few studies performed by health professionals are
based on such instruments [17]. In this context, this
project suggests the development and validation of a MI
skill assessment method -as an essential and comple-
mentary element- more appropriately adapted to our
environment: the Motivational Interviewing Assessment
Scale (EVEM in Spanish).
Finally, two general conclusions can be drawn from
the data available on general practitioners’ professional
training [18,19]: 1) Although physicians devote many
hours to their training, such training does not seem to
benefit patients’ health; 2) The type of education which
better improves patients’ health is interactive training
(joint work tutor-learner) and mixed training (lecture
with interaction). We also know that training in clinical
Interviewing is inadequate in official health professional
training programs in Spain. Thus, minimum standards
for clinical Interviewing are not provided in health pro-
fessional training programs and the courses including it
are voluntary, unregulated and are generally performed
in post grade programs, as if this professional compe-
tence was not important enough or had no clinical
impact at all. In this paper, an innovative, standardized
MI training program will be implemented by following
the models already established in scientific literature
[20] -and currently included in the MINT network
(Motivational Interviewing Network of trainers). We will
follow the eight stages described by Moyers and Miller
[21]; similarly, economical training technologies -as e-
learning- will be used and educational feedback will be
provided to improve clinical skills.
Research Objectives
The primary objective of this study is to verify the effec-
tiveness of a multi-factorial intervention based on MI
and performed by GPs specifically trained to improve
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contrast with the usual brief advice.
T h es p e c i f i co b j e c t i v eo ft h i ss t u d yi sa s s e s s i n g
whether after a 12-month follow-up, a multi-factorial
intervention based on MI achieves:
￿ To improve lipid levels in patients;
￿ To reduce cardiovascular risk;
￿ To improve patients’ diet (adherence to the Mediter-
ranean diet and reduction of saturated fat intake);
￿ To increase physical activity;
￿ To reduce body weight in patients with overweight
or obesity;
￿ To improve adherence to prescribed hypolipidemic
drugs.
Our complementary objectives are:
￿ To check the effect of the MI training program on
the participating GPs allocated to the experimental
group.
￿ To validate a measuring instrument specifically
designed for assessing the use of MI (EVEM scale)
among GPs.
Methods/Design
Study Design
It is an open, parallel, multicentre, cluster, controlled,
randomized clinical trial. Two groups will be monitored
for a 12-month period. Figure 1 shows a scheme of the
study design.
The intervention will be based on the implementation
of MI during contacts with patients, instead of the usual
brief advice method. The aim is to check whether this
approach is more effective in promoting cardioprotective
behaviors in patients (heart protective diet, physical
activity, weight loss), and in improving lipid level con-
trol, thus reducing cardiovascular risk.
Sample Size
Basing on the results and on preliminary estimates
[22-24], 256 patients should be recruited for an individual
randomized study, to reach a variation coefficient of 40
mg/dl in total cholesterol levels, a difference of 15 mg/dl
in the mean value of total cholesterol level among
patients of the Intervention Group -IG- and the Control
Group -CG-, and a deviation alpha = 0.05, beta = 15%.
As this is a cluster randomized study, “design effects”
have been considered. The correlation intraclass coeffi-
cient estimates in cluster controlled clinical trials in pri-
mary care are generally below 0.05 [25]. For a cluster
size of 15, this controlled clinical trial has a design effect
of 1.7. Taking this value into consideration, the sample
size should be 436 subjects (218 for each group).
Participants
General Practices
We plan to recruit 48-50 randomized GPs trained to
assist 8-10 patients each. The physicians recruited must
work in a public primary care center in Spain and
express commitment to keep their post during the field
work period of the study.
Patients
The inclusion criteria are:
1) Patients of both genders, aged between 40 and 75
years.
2) Patients must be assisted by their family doctor.
3) Patients must be diagnosed with dyslipidemia in
accordance with the following classification [26]:
￿ Defined hypercholesterolemia: total cholesterol
>250 mg/dl (6.45 mmol/l) and triglycerides <200
mg/dl (2.26 mmol/l);
￿ Hypertriglyceridemia: total cholesterol <200
mg/dl (5.17 mmol/l) and triglycerides >200 mg/
dl (2.26 mmol/l).
￿ Mixed hyperlipidemia: total cholesterol >200
mg/dl (5.17 mmol/l) and triglycerides >200 mg/
dl (2.26 mmol/l).
4) No lipid-lowering drug therapy at the time of
inclusion.
5) Capacity to provide informed consent.
The exclusion criteria are:
￿ Patients with pathologies that can produce second-
ary dyslipidemIa and need pharmacological therapy;
￿ Subjects with previous cardiovascular events or
other chronic conditions as diabetes or severe
Chronic obstructive pulmonary disease, cancer, ser-
ious liver alterations, chronic renal failure, at-risk or
alcoholic drinkers, drug users;
￿ Patients on long-term sick leave;
￿ Pregnant or nursing women;
￿ Subjects unable to comply with the study proce-
dures for their personal characteristics (cognitive
level, altered psychological status, etc)
Randomisation
The participating practitioners will be allocated to each
a r mo ft h es t u d yb yu s i n gt h es i m p l er a n d o m i z a t i o n
method in a 1:1 ratio for IG and CG, using the software
EPIDAT 3.0.
Study Intervention
Patients in the IG will be assisted by a GP who will use
the MI approach, while patients in the CG will be
assisted as usual (informative model). Both groups of
physicians will base their therapy on the scientific
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the treatment of dyslipidemia.
Intervention Group
IG practitioners will assist their patients using the MI
method in compliance with clinical protocol
recommendations.
In this study, a MI training program will be imple-
mented following the models already established in
scientific literature and in recognized works by interna-
tional authors currently associated in the Motivational
Interviewing Network of Trainers (MINT), which meets
all international research and dissemination standards.
 
 
 
 
 
 
 
 
 
 
 
TARGET POPULATION
STUDY POPULATION
Patients  meeting eligibility criteria:
-40 to 75 years, both genders
-Dyslipemia 
Exclusion Criteria:
- Secondary
hypercholesterolemia.
- Familial high-density 
lipoprotein deficiency.
-CVD, Diabetes, COPD, severe 
liver disease, kidney disease
-Psychiatric disorders or 
substance abuse 
-Prolonged sick leave.
-Pregnant or nursing.
Randomization
48-50 General Practitioners
(n=436 patients)
EXPERIMENTAL GROUP (24-25 GPs) 
218 patients (8-10/doctor)
Pre-inclusion interview (V-1)
Initial assessment 
CONTROL GROUP (24-25 GPs)
218 patients (8-10/doctor)
Pre-inclusion interview (V-1)
Initial assessment
Baseline assessment (V0)
Motivational Interviewing
Baseline assessment (V0) 
Usual intervention 
Follow-up, intervention and assessment 
2, 4, 8 , 12  months
Degree of lipid level control and CV risk 
assessment 
Follow-up, intervention and assessment 
2, 4, 8 , 12  months
Degree of lipid level control and CV risk 
assessment 
Data analysis
Conclusions
Research Training Program
GPs: General Practices
Figure 1 Scheme of the Dislip-EM study design.
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GPs should be able to perform [21]:
1. General spirit (collaborative thinking, respect for
patients’ personal autonomy...);
2. Patient-centered counseling (this involves the com-
fortable practice of open-ended questions, affirmation,
summaries, and particularly the skill of accurate empa-
thy as described by Rogers [10]);
3. Ability to recognize patients’ change talk or coun-
ter-change arguments.
4. Eliciting and strengthening patients’ change talk;
5. Rolling with resistance and counter-change
arguments;
6. Developing a reasonable change plans suitable for
the patient.
7. Consolidating patient’s commitment by helping
them develop specific change attitudes.
8. Ability to combine MI with other intervention
methods.
The training program on MI (Figure 2) will be imple-
mented with the IG practitioners. The program includes
classroom workshops and online training through a
website-based training platform in Moodle format
available at http://www.doctutor.es, where the tasks are
developed and IG practitioners are monitored. The
baseline Motivational Interviewing level of physicians is
a s s e s s e db yu s i n gt h eE V E Ms c a l e( T a b l e1 )a n dat w o -
station clinical interview (OSCE model) with standar-
dized patients and video recordings. Improvements in
the level of MI skills will be assessed watching the video
recordings at first visit and four visit. This study intro-
duced an innovative learning technique which consists
of watching the videotapes of the interviews uploaded
on a virtual library with restricted access. Each partici-
pant can watch their interviews and assess their own
position on the EVEM scale. Participants’ self-assess-
ment is contrasted by expert testers. Subsequently,
through the platform or via e-mail, testers provide the
practitioners with feedback for them to reflect on the
results (motivational teaching method, in contrast with
the directive method).
The sequential development of the MI training pro-
gram consists of the following sections:
1. All practitioners -IG and CG- will attend a four-
hour workshop where the study and clinical practice
guides on dyslipidemia will be presented.
EVEM 
4 
First 
day 
Randomized 
assignation 
Control 
Group 
Intervention 
Group 
Workshop 
Presentation 
Guides 
Dyslipidemia 
SP 
two 
Clinical 
Cases 
SP 
two 
Clinical 
Cases 
Real 
patient 
video-
recording 
Month 2 
Real 
patient 
video-
recording 
Month 4 
Real 
patient 
video-
recording 
Month 8 
Real 
patient 
video-
recording 
Month 12 
MI  
Work- 
shop 
P 
B 
I 
P 
B 
I 
P 
B 
I 
MI  
Work- 
shop 
EVEM 
SP  
EVEM 
SP  
EVEM 
SP  
EVEM 
2  
EVEM 
3  
EVEM 
4  
EVEM 
3 
EVEM 
1  
EVEM 
2 
EVEM 
1  
Field Work 
Figure 2 Training program on Motivational Interview of Dislip-EM study. MI: Motivational Interview; SP: Standard Patients; PBI: Problem
Based Interview; EVEM: rating scale of motivational interviewing.
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held focusing on the eight internationally recognized
stages (16 hours distributed in two consecutive days).
The workshop is to be held in the three sites of the pro-
ject with the same trainer. All workshops will be video
recorded to verify that the eight stages were explained.
3. Video recording of two interviews with standardized
patients (trained by the same trainers) before and imme-
diately after the workshop on MI.
4. After watching the videotapes, feedback will be pro-
vided by a MI expert in person.
5. Creation of a video library in Vimeo http://www.
vimeo.com with all the videotapes randomly numbered
(combining all the sites).
6. “Educational micropills” will be forwarded to the
participants via Internet and short messages during the
months after the course (up to a year after the begin-
ning of the course).
7. Interviews with the real dyslipidemic patients parti-
cipating in the study (2-4-8-12-month visits) will be
video recorded.
8. Task performance and feedback: critical incident,
reading and commenting an article on Motivational
Interviewing, watching their own video recordings
uploaded on the platform, attendance to one or two
Problem Based Interview (PBI) sessions [27] to watch
and analyze a video with the IG researchers of their city.
9. At the end of the training period, a one-hour pre-
sentation on MI will be given by GPs to their team
mates.
One of the most innovative aspects of the program is
the use of modern online technologies:
1. Second life: The project was designed by a group
of experts who live in different cities in Spain, and
who make up the coordination team. This site allows
researchers to hold regular meetings on-line. Follow-
up will be performed through scheduled meetings
using semFYC island software http://secondlife.com/.
2. Skype. Some of the training program coordinators
will meet via skype. The option “share screen” will
allow the team to prepare new documents in real
time.
3. Moodle platform. Moodle is a Course Manage-
ment System (CMS), also known as a Learning Man-
agement System (LMS) or a Virtual Learning
Environment (VLE). It is a free web application that
educators can use to create effective online learning
sites http://www.moodle.org. The intervention group
monitors the study using the Moodle platform,
which contents are edited and integrated into the
website Doctutor, thus allowing researchers consult
all documents, materials and project guides, monitor
the schedule, perform training tasks, interact via a
blog, and receive feedback from their tutors (E-
learning). Expert trainers/tutors can also use a plat-
form for collaborative work.
4. E-mail and short messages. Each month, partici-
pants will receive “training micropills” on their e-
mail address apmotivacional@gmail.com. These
Table 1 EVEM scale version 1.3
ID code:
Behavior studied:
Time devoted to the interview (min):
To what extend does the professional... 0 1 2 NA
1. tune with the patient through non-verbal communication?
2. show empathy at appropriate times?
3. make proper patient positioning concerning the behavior in question?
4. works consistently with the positioning of the patient throughout the interview?
5. use open-end questions?
6. validates genuinely the patient (abilities, skills, effort, interest...) ?
7. perform reflective listening?
8. make summaries of the information provided by the patient?
9. strengthens change talk?
10. give attention to the patient’s commitment to change?
11. identifies resistance to change and use specific strategies to avoid and handle them?
12. provides information adapted to the patient’s difficulties and needs?
13. promotes the definition and/or prioritization of the objectives of change with the patient?
14. negotiates and test a feasible action plan considering the patient’s options?
15. once change has started, develop maintenance strategies with the patient?
16. in case of relapse, create a climate of acceptance, trying to promote patient’s self-efficiency?
NA: Not Applicable
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ing. They can also be accessed via Moddle.
- Videotape Analysis. It is performed using the EVEM
scale (Table 1), which is currently being concurrently
validated in the project itself. This scale will be used by
GPs for self-assessment (self-perception) and by the
researchers (peer review). The inter-observer concor-
dance level will be analyzed.
Control Group
The GPs assigned to this group will provide the usual
“brief counseling” based on medical advice, where
patients will be warned about the need to change their
habits into healthier ones. GPs will provide the recom-
mendations included in the clinical protocols concerning
diet, physical activity and tobacco consumption. The 16-
hour workshop on motivational Interviewing will be also
provided to the CG practitioners once the study is
completed.
Outcome Measurement and Tools
At month 2, 4, 8 and 12, the results will be assessed
using the following measuring instruments and
procedures:
-Blood analysis: total cholesterol levels, LDL and HDL
cholesterol, and triglycerides.
-Cardiovascular risk: to assess cardiovascular risk, we
will use the SCORE table for low-risk European popu-
lation [28,29], the table of the REGICOR study [30],
and Framingham’s equations [31] by using the applica-
tion Circe.exe http://www.1aria.com/sections/cardio-
vascular/hipertension/HipertensionCalculadorasRiesgo.
aspx that, when data are entered, automatically calcu-
lates the figures corresponding to each cardiovascular
risk function.
-Anthropometric data: weight, height and body mass
index (BMI: kg/m2).
-Overweight/Obesity: waist circumference measure-
ment according to the criteria of the World Health
Organization [32] and the amendments proposed by the
Sociedad Española para el Estudio de la Obesidad
(SEEDO) for Spain [33].
-Diet: questionnaire on adherence to the Mediterra-
nean diet, validated for Spain [34].
-Physical activity and sedentary behavior: the Interna-
tional Physical Activity Questionnaire -IPAQ- [35] will
be used to quantify the level of physical activity.
The primary analysis will be centered on the level of
accomplishment of the recommended objectives in
patients with dyslipidemia according to recommenda-
tions of the European Cardiovascular Prevention Guide,
Spanish adaptation of 2008 [36]:
- Total cholesterol < 200 mg/dl (5.2 mmol/l) and LDL
cholesterol <130 mg/dl (3.4 mmol/l).
- Severe hyperlipidemia total cholesterol ≥ 320 mg/dl(8
mmol/l) or LDL cholesterol ≥ 240 mg/dl (6 mmol/), con-
sidered high-risk patients: to reduce total cholesterol <175
mg/dl - <4.5 mmol/l- (155 mg/dL if possible) and LDL
cholesterol <100 mg/dl - <2.5 mmol/l- (<80 mg/dL if
possible).
Trial Procedure
Recruitment
Practice recruitment A number of practitioners were
invited through different means (Sociedad Española de
Medicina Familiar y Comunitaria, project coordinators’
peers, scientific events, etc) to participate in the study.
Those who were willing to participate (a total of 50 GPs
from different regions in Spain) signed a commitment
and confidentiality document.
Patient recruitment Patients will be recruited using the
case finding method; the procedure will consist on
actively searching subjects who are eligible and invite
them to participate in the study in a consecutive way,
until the sample size planned is reached.
Analysis
Primary Analysis
The primary objective of the study is to assess changes
and differences in cholesterol levels and cardiovascular
risk between both groups, in terms of whether the
recommended therapeutic objectives were achieved or
not.
S o m eo ft h es e c o n d a r yv a r i a b l e so ft h es t u d ya r et o
take anthropometric measures, which will allow
researchers assess changes in patients’ weight and body
composition (weight, height, BMI, waist circumference),
as well as assessing their degree of adherence to the
Mediterranean diet and evaluating changes in physical
activity habits.
All intervention effectivene s sa n a l y s i sw i l lb ep e r -
formed by intention to treat complying with the
cluster design and considering two levels (practi-
tioner and patient). The multi-level logistic regres-
sion analysis will be performed using MLwiN version
2.02.
Process Evaluation
The evaluation process will allow us to verify and moni-
tor the impact of the different aspects of the interven-
tion:
-Video recordings with standardized and real
patients.
-Monthly contacts via telephone and at least one
visit to the center of each of the participating
researchers.
-Validation and use of EVEM for the evaluation.
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the interview, professionals will fill in an autocheck-
list by using the EVEM questionnaire (table 1).
Discussion
This project represents an attempt to advance on an
aspect of health care that is considered key in Western
health systems today due to its high magnitude: testing
t h em o s te f f e c t i v ep r e v e n t i v ea p p r o a c h e si nt h ef i g h t
against Heart Disease in primary care.
There are few publications that demonstrate the effec-
tiveness of nonpharmacological interventions in the
treatment of dyslipidemia. Demonstrating which of the
two interventions tested here is more effective can have
a major impact on clinical practice when designing and
proposing clinical protocols for the prevention of CRFs.
Clinical Interviewing skills and health education are
the essential strategy used by general practitioners with
their patients. Obtaining scientific evidence on the effec-
tiveness of MI in primary care through strict monitoring
of the training methods, and controlling the integrity of
the therapies applied, will allow us to have economical
brief, effective and applicable techniques to help patients
change their health habits and achieve better health
outcomes.
This study is one of the first attempts to assess to
what extent the motivational approach -as defined in
MI (and their EVEM adaptation) is applied by GPs. The
results obtained will help us understand the practical
effectiveness of this approach, including its limitations
and actual impact on cardiovascular health. If this
method proved to be effective, our intention is to disse-
minate and promote that interventions based on the
training model tested would be included into the clinical
practice guide usually employed by family doctors.
Protection Against Bias
The study is open, so the intervention can not be
masked. Therefore both, patients and practitioners, will
know who is involved in the intervention, and this could
condition their response (Hawthorne effect), specially in
the control group. Just the fact that the participants are
identified and express their wish to participate in the
study, and subjecting them to more intensive monitor-
ing than usual, could make them more willing to follow
medical advice.
To control and monitor the interventions, some of the
clinical interviews will be video recorded, which may
lead to a bias. To compensate this, our intention is to
ensure that both groups differ only in the type of inter-
vention, and to verify that only the physicians of the
experimental group perform MI, while the control
group does not use this approach.
Logically, the fact that doctors know that they are
being observed may affect their performance and lead
them to change their behavior, but there is wide experi-
ence in the use of observation methods similar to the
one used here confirming that, in real practice, it is very
difficult to modify the style of consultation used. In any
case, if there is any bias, it will not be differential, since
both groups are subject to the same observation proce-
dure. Changes in patient behavior tend to be even lower
[37].
The study will be randomized by cluster (professional)
to avoid contamination bias and ensure recruitment of
the adequate number of patients. We hope that rando-
mization will allow to reach a balance between the two
groups concerning the characteristics both of the physi-
cians and the patients involved. Potential confounding
factors are to be controlled by multivariate analysis.
Appendix
Participants in the Collaborative Group of the Dislip-
EM Study
1. Emilio García Criado (CS Fuensanta. Córdoba.
Spain)
2 .M a r í aP i n e d aA l o n s o( C SL e v a n t es u r .C ó r d o b a .
Spain)
3. Ana Roldán Villalobos (CS Huerta de la Reina. Cór-
doba. Spain)
4. Antonio Pérez Fuentes (Consultorio Villafranca de
Córdoba. Spain)
5. Mª José Acosta García (CS Adamuz. Spain)
6. Victoriano Rodríguez Navarro (CS La Carlota.
Spain)
7. Isabel de Andrés Cara (CS Levante sur. Córdoba.
Spain)
8. Antonio León Dugo (CS Levante sur. Córdoba.
Spain)
9. Alfredo Ortiz Arjona (CS La Carlota. Spain)
10. Pilar Serrano Varo (CS Posadas. Spain)
11. Antonio Valero Martín (Consultorio Villafranca de
Córdoba)
12. Juan Manuel Parras Rejano (CS Peñarroya. Spain)
13. Rosana Izquierdo Fernández (CS Coruxo. Spain)
14. José Antonio Pérez Vences (CS Rúa Cuba. Spain)
15. Antonio Fernández Crespo (CS Colmeiro. Spain)
16. Susana Hernaiz Valero (CS Val Miñor. Spain)
17. Mª Jesús Cobas Martínez (CS Matamá. Spain)
18. Neus Fernández Danés (ABS Centre L’ Hospitalet
de Llobregat. Spain)
19. Francisca Pérez Fuentes (CS Virgen Linarejos.
Linares. Spain)
20. Clara Soria López (CS Virgen Concha. Zamora.
Spain)
21. Juan Carlos Verdes-Montenegro Atalaya (CS
Comuneros. Burgos. Spain)
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